secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001104659-24-042502
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics CFO Peter Pfreundschuh to resign; Robin Swartz appointed as principal financial officer
--------------------------------------------------------------------------------

- CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.
- Robin Swartz, current COO, appointed principal financial and accounting officer effective April 12.
- Pfreundschuh receives salary continuation for 12 months, prorated 2024 bonus, and health insurance.
- Unvested equity awards continue to vest during consulting period up to ~July 2024.
- Separation Agreement includes release of claims and non-disparagement obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924042502/0001104659-24-042502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924042502/tm2410417d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-042502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer